Analysts expect that AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will report ($0.44) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for AMAG Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.36). AMAG Pharmaceuticals reported earnings of ($0.60) per share during the same quarter last year, which would indicate a positive year over year growth rate of 26.7%. The business is expected to announce its next quarterly earnings report on Thursday, February 6th.
According to Zacks, analysts expect that AMAG Pharmaceuticals will report full-year earnings of ($2.60) per share for the current year, with EPS estimates ranging from ($2.62) to ($2.55). For the next financial year, analysts forecast that the company will post earnings of ($1.28) per share, with EPS estimates ranging from ($3.31) to ($0.55). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for AMAG Pharmaceuticals.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its earnings results on Friday, November 1st. The specialty pharmaceutical company reported ($0.70) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.51) by ($0.19). AMAG Pharmaceuticals had a negative return on equity of 34.59% and a negative net margin of 88.54%. The company had revenue of $84.13 million for the quarter, compared to the consensus estimate of $88.25 million. During the same quarter last year, the business earned $0.89 EPS. AMAG Pharmaceuticals’s quarterly revenue was down 31.2% compared to the same quarter last year.
In related news, major shareholder Armistice Capital Master Fund acquired 30,466 shares of the company’s stock in a transaction dated Friday, January 10th. The stock was bought at an average cost of $11.31 per share, with a total value of $344,570.46. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.90% of the company’s stock.
Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC grew its position in AMAG Pharmaceuticals by 6,500.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 13,200 shares of the specialty pharmaceutical company’s stock valued at $161,000 after buying an additional 13,000 shares during the period. Millennium Management LLC raised its position in shares of AMAG Pharmaceuticals by 727.4% during the 3rd quarter. Millennium Management LLC now owns 802,607 shares of the specialty pharmaceutical company’s stock worth $9,270,000 after purchasing an additional 705,600 shares during the last quarter. Permanens Capital L.P. lifted its stake in AMAG Pharmaceuticals by 53.0% in the 3rd quarter. Permanens Capital L.P. now owns 407,811 shares of the specialty pharmaceutical company’s stock valued at $4,710,000 after buying an additional 141,311 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in AMAG Pharmaceuticals by 12.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 101,700 shares of the specialty pharmaceutical company’s stock valued at $1,175,000 after buying an additional 10,900 shares in the last quarter. Finally, California Public Employees Retirement System lifted its stake in AMAG Pharmaceuticals by 11.8% in the 3rd quarter. California Public Employees Retirement System now owns 80,327 shares of the specialty pharmaceutical company’s stock valued at $928,000 after buying an additional 8,474 shares in the last quarter.
NASDAQ AMAG traded down $1.83 on Friday, hitting $9.56. The company’s stock had a trading volume of 232,044 shares, compared to its average volume of 834,007. The company’s 50-day moving average is $11.85 and its 200 day moving average is $10.90. The firm has a market cap of $396.75 million, a PE ratio of -1.13 and a beta of 0.42. AMAG Pharmaceuticals has a 1-year low of $6.81 and a 1-year high of $17.13. The company has a quick ratio of 1.53, a current ratio of 1.67 and a debt-to-equity ratio of 0.58.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.
Read More: Treasury Bonds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.